Literature DB >> 23357299

Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels.

Beatriz Sanchez-Correa1, Juan M Bergua, Carmen Campos, Inmaculada Gayoso, Maria Jose Arcos, Helena Bañas, Sara Morgado, Javier G Casado, Rafael Solana, Raquel Tarazona.   

Abstract

BACKGROUND: Several evidences support the existence of cytokine deregulation in acute myeloid leukemia (AML) patients that may be associated with pathogenesis, disease progression and patient survival.
METHODS: In the present study, we analyzed plasma levels of pro- and anti-inflammatory cytokines in AML patients and age-matched healthy donors. TNF-α, IL-6, IL-1β, IL-2, IFN-γ, IL-17A, IL-12p70, IL-8, IL-10, IL-4 and IL-5 were analyzed using fluorescent bead-based technology and TGF-β by ELISA technique. Because age-associated differences in cytokine profiles have been described, patients and healthy individuals were divided into two age groups: up to 65 years and over 65 years.
RESULTS: Our results showed that plasma TNF-α, IL-6 and IL-10 levels were higher in AML patients from both groups of age. IL-8 was increased in AML patients less than 65 years while the plasma concentrations of IL-4, IL-5 and IL-12p70 were significantly higher only in elderly AML patients compared with aged-matched healthy controls. Moreover, plasma levels of IL-6 and IL-10 were associated with patient survival and event-free survival.
CONCLUSIONS: An aberrant production of the pro-inflammatory cytokines IL-6 and TNF-α and the anti-inflammatory cytokine IL-10 is observed in AML patients. Low levels of IL-6 and high levels of IL-10 represent favorable prognostic factors for survival in AML patients. These results support the idea that cytokine deregulation may be useful as a marker for predicting clinical evolution in AML patients.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23357299     DOI: 10.1016/j.cyto.2012.12.023

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  58 in total

1.  Association of Interleukin-4 Polymorphisms With Breast Cancer in Taiwan.

Authors:  Chia-Wen Tsai; Chien-Chih Yu; DA-Tian Bau; Chin-Nan Chu; Yun-Chi Wang; Wen-Shin Chang; Zhi-Hong Wang; Liang-Chih Liu; Shao-Chun Wang; Cheng-Chieh Lin; Ting-Yuan Liu; Jan-Gowth Chang
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

Review 3.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

4.  Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.

Authors:  Syed M Kazmi; Naveen Pemmaraju; Keyur P Patel; Philip R Cohen; Naval Daver; Kathy M Tran; Farhad Ravandi; Madeleine Duvic; Guillermo Garcia-Manero; Sherry Pierce; Aziz Nazha; Gautam Borthakur; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-12-24

5.  Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Authors:  Katelyn Melgar; Morgan M Walker; LaQuita M Jones; Lyndsey C Bolanos; Kathleen Hueneman; Mark Wunderlich; Jian-Kang Jiang; Kelli M Wilson; Xiaohu Zhang; Patrick Sutter; Amy Wang; Xin Xu; Kwangmin Choi; Gregory Tawa; Donald Lorimer; Jan Abendroth; Eric O'Brien; Scott B Hoyt; Ellin Berman; Christopher A Famulare; James C Mulloy; Ross L Levine; John P Perentesis; Craig J Thomas; Daniel T Starczynowski
Journal:  Sci Transl Med       Date:  2019-09-04       Impact factor: 17.956

6.  Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance.

Authors:  Alexandra M Stevens; Jennifer M Miller; Jaime O Munoz; Amos S Gaikwad; Michele S Redell
Journal:  Blood Adv       Date:  2017-08-01

7.  The Expression of Interferon Gamma (IFN-γ) and Interleukin 6 (IL6) in Patients with Acute Lymphoblastic Leukemia (ALL).

Authors:  Mehdi Allahbakhshian Farsani; Masomeh Kamel; Mahdieh Mehrpouri; Reza Shiri Heris; Mohsen Hamidpour; Sina Salari; Mohamad Hosien Mohamadi
Journal:  Pathol Oncol Res       Date:  2018-11-15       Impact factor: 3.201

Review 8.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

9.  Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.

Authors:  Dewan Md Sakib Hossain; Cedric Dos Santos; Qifang Zhang; Anna Kozlowska; Hongjun Liu; Chan Gao; Dayson Moreira; Piotr Swiderski; Agnieszka Jozwiak; Justin Kline; Stephen Forman; Ravi Bhatia; Ya-Huei Kuo; Marcin Kortylewski
Journal:  Blood       Date:  2013-10-29       Impact factor: 22.113

10.  The impact of inflammation and cytokine expression of PM2.5 in AML.

Authors:  Tingting Chen; Juan Zhang; Hui Zeng; Yue Zhang; Yong Zhang; Xiaohuan Zhou; Dong Zhao; Yingmei Feng; Hebing Zhou
Journal:  Oncol Lett       Date:  2018-06-13       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.